Peritoneal fibrosis and epigenetic modulation

2020 ◽  
pp. 089686082093823
Author(s):  
Yi Wang ◽  
Yingfeng Shi ◽  
Min Tao ◽  
Shougang Zhuang ◽  
Na Liu
Keyword(s):  
End Stage Renal Disease ◽  
Noncoding Rnas ◽  
Epigenetic Modifications ◽  
Common Complication ◽  
Peritoneal Fibrosis ◽  
Ultrafiltration Failure ◽  
Epigenetic Modulation ◽  
Stage Renal Disease ◽  
End Stage

Peritoneal dialysis (PD) is an effective treatment for patients with end-stage renal disease. However, peritoneal fibrosis (PF) is a common complication that ultimately leads to ultrafiltration failure and discontinuation of PD after long-term PD therapy. There is currently no effective therapy to prevent or delay this pathologic process. Recent studies have reported epigenetic modifications involved in PF, and accumulating evidence suggests that epigenetic therapies may have the potential to prevent and treat PF clinically. The major epigenetic modifications in PF include DNA methylation, histone modification, and noncoding RNAs. The mechanisms of epigenetic regulation in PF are complex, predominantly involving modification of signaling molecules, transcriptional factors, and genes. This review will describe the mechanisms of epigenetic modulation in PF and discuss the possibility of targeting them to prevent and treat this complication.

scholarly journals The Role of Tyrosine Kinase Receptors in Peritoneal Fibrosis

2015 ◽  
Vol 35 (5) ◽  
pp. 497-505 ◽  
Author(s):  
Li Wang ◽  
Shougang Zhuang
Keyword(s):  
Tyrosine Kinases ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β1 ◽  
Peritoneal Fibrosis ◽  
Functional Changes ◽  
Ultrafiltration Failure ◽  
Stage Renal Disease ◽  
End Stage

Peritoneal dialysis (PD) is a modality for treatment of patients with end-stage renal disease (ESRD) that depends on the structural and functional integrity of the peritoneal membrane. However, long-term PD can lead to morphological and functional changes in the peritoneum; in particular, peritoneal fibrosis has become one of the most common complications that ultimately results in ultrafiltration failure (UFF) and discontinuation of PD. Several factors and mechanisms such as inflammation and overproduction of transforming growth factor-β1 have been implicated in the development of peritoneal fibrosis, but there is no effective therapy to prevent or delay this process. Recent studies have shown that activation of multiple receptor tyrosine kinases (RTKs) is associated with the development and progression of tissue fibrosis in various organs, and there are also reports indicating the involvement of some RTKs in peritoneal fibrosis. This review will describe the role and mechanisms of RTKs in peritoneal fibrosis and discuss the possibility of using them as therapeutic targets for prevention and treatment of this complication.

Frequency of Gastrointestinal Diseases in Patients with End-Stage Renal Disease Treated with Long Term Dialysis

2018 ◽  
Vol 2 (2) ◽  
pp. 105-112
Author(s):  
Lutfi Zylbeari ◽  
Zamira Bexheti ◽  
Gazmend Zylbeari ◽  
Ferizate Haxhirexha ◽  
Kastriot Haxhirexha
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Gastrointestinal Diseases ◽  
Stage Renal Disease ◽  
End Stage

Long-term hemodialysis therapy in neonates and infants with end-stage renal disease: a 16-year experience and outcome

2015 ◽  
Vol 31 (2) ◽  
pp. 305-313 ◽  
Author(s):  
Shirley Pollack ◽  
Israel Eisenstein ◽  
Mahdi Tarabeih ◽  
Hadas Shasha-Lavski ◽  
Daniella Magen ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
Neonates And Infants

Impact of statin on long-term outcome among patients with end-stage renal disease with acute myocardial infarction (AMI): a nationwide case–control study

2021 ◽  
pp. postgradmedj-2019-137292
Author(s):  
Feng-You Kuo ◽  
Wei-Chun Huang ◽  
Pei-Ling Tang ◽  
Chin-Chang Cheng ◽  
Cheng-Hung Chiang ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Survival Rate ◽  
Statin Therapy ◽  
End Stage Renal Disease ◽  
Term Survival ◽  
Receptor Blockers ◽  
Stage Renal Disease ◽  
End Stage ◽  
Statin Use

BackgroundUse of statin has been associated with reduced risk of cardiovascular diseases events and mortality. However, in patients with end-stage renal disease (ESRD), the protective effects of statin are controversial. To evaluate the impact of chronic statin use on clinical outcomes of patients with acute myocardial infarction (AMI) with ESRD.MethodsWe enrolled 8056 patients with ESRD who were initially diagnosed and admitted for first AMI from Taiwan’s National Health Insurance Research Database. Of which, 2134 patients underwent statin therapy. We randomly selected and use age, sex, hypertension, diabetes mellitus (DM), peripheral vascular diseases (PVD), heart failure (HF), cerebrovascular accidents (CVA), chronic obstructive pulmonary disease, matched with the study group as controls (non-stain user). We compared the effects of statin use in term of all-cause death among patients with AMI with ESRD.ResultsStatin use resulted in a significantly higher survival rate in patients ith AMI with ESRD compared with non-statin users. After adjusted the comorbidities the male patients and patients with DM, PVD, HF and CVA had lower long-term survival rate (all p<0.001). Patients who underwent percutaneous coronary intervention (p<0.001), ACE inhibitors/angiotensin II receptor blockers (p<0.001), β receptor blockers (p<0.001) and statin therapy (p=0.007) had better long-term survival rate. Patients with AMI with ESRD on statin therapy exhibited a significantly lower risk of mortality compared with non-statin users (p<0.0001).ConclusionAmong patients with ESRD with AMI, statin therapy was associated with reduced all-cause mortality.

scholarly journals SP347MORTALITY AND BONE SAFETY OUTCOMES IN PATIENTS WITH END-STAGE RENAL DISEASE RECEIVING LANTHANUM CARBONATE: A LONG-TERM, OBSERVATIONAL STUDY

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii226-iii227
Author(s):  
Alastair Hutchison ◽  
Ravi Thadhani ◽  
Gillian Hall ◽  
Andrew Whelton ◽  
Heinrich Achenbach ◽  
...  
Keyword(s):  
Observational Study ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Lanthanum Carbonate ◽  
Safety Outcomes ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document